Physician profile
Mark S Foley
NPI 1407849995
$1,699.81
in general payments reported to CMS, 2019-2025
20 companies · $477 in 2025
The $477 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225 · 2020: $51.37 · 2021: $148 · 2022: $135 · 2023: $220 · 2024: $444 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995 · Entertainment: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.40 |
| Entertainment | $145.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $279.62 | 2024-2025 | Tepezza |
| Alcon Vision LLC | $198.62 | 2019-2025 | Precision7, Rocklatan |
| Sun Pharmaceutical Industries INC. | $191.18 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.02 | 2019-2021 | |
| Optos, INC. | $145.52 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb Americas INC. | $138.36 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Horizon Therapeutics Plc | $103.89 | 2019-2023 | Tepezza |
| Allergan, INC. | $77.44 | 2019-2022 | |
| Oyster Point Pharma, INC. | $54.41 | 2022-2023 | Tyrvaya |
| Astellas Pharma US INC | $52.26 | 2024-2025 | Izervay |
| Dompe US, INC. | $47.96 | 2019-2024 | Oxervate |
| Lkc Technologies, INC. | $45.45 | 2024 | |
| Kala Pharmaceuticals, INC. | $40.11 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $34.71 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $29.63 | 2019-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $28.39 | 2024 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $20.81 | 2021 | |
| Alcon Research LLC | $16.18 | 2019 | |
| Aerie Pharmaceuticals, INC. | $15.82 | 2019 | |
| Abbvie INC. | $12.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.